Stay updated with breaking news from Igor Odintsov. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Helsinn presents newly available data on vepafestinib at IASLC 2022 World Conference on Lung Cancer Lugano, Switzerland, August 8, 2022 - Helsinn Group ("Helsinn"), a fully integrated
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
As Russia-Ukraine tensions rise, dominating international headlines, director Maria...
NRG1 gene fusion. The CRESTONE study is currently enrolling at sites across the United States. "Here we observed that NRG1 fusions activated HER3 and downstream signaling mediators such as AKT in a pancreatic cell line," said Igor Odintsov, MD, Research Fellow at MSK and lead author of the poster presentation. "Treatment with seribantumab was able to inhibit phosphorylation of the activated HER3 and AKT in the same cell line, and subsequent treatment of an APP-NRG1 fusion-positive pancreatic PDX model with seribantumab robustly inhibited tumor growth at clinically achievable doses." Regressi...
Elevation Oncology Announces Clinical Cancer Research Publication Highlighting the Specific Inhibition of HER3 by Seribantumab in Preclinical NRG1 Fusion Models - Results show seribantumab efficiently inhibited HER3 and the entire ERBB family signaling pathway and established a biologically effective dose range for tumors driven by an NRG1 fusion - - Seribantumab is currently being evaluated in the tumor-agnostic Phase 2 CRESTONE trial for patients with any solid tumor harboring an NRG1 fusion - News provided by Share this article Share this article NEW YORK, April 6, 2021 /PRNewswire/ -- El...